Dyne Therapeutics, Inc. Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount
Dyne Therapeutics, Inc. (DYN) reported Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount of -$93.70 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate · last filed 2026-03-02
- Dyne Therapeutics, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2025 was -$93.70M.
- Dyne Therapeutics, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2024 was -$66.66M.
- Dyne Therapeutics, Inc. effective income tax rate reconciliation at federal statutory income tax rate, amount for fiscal 2023 was -$49.55M.
| Period end | Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount 12 month |
|---|---|
| 2025-12-31 | -$93.70M 10-K · filed 2026-03-02 |
| 2024-12-31 | -$66.66M 10-K · filed 2026-03-02 |
| 2023-12-31 | -$49.55M 10-K · filed 2026-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |